Pretreatment red blood cell distribution width may be a potential biomarker of prognosis in urologic cancer: a systematic review and meta-analysis.
Published
March 14, 2023
Journal
Biomarkers in medicine
PICOID
de0bfd71
DOI
Citations
2
Keywords
cancer-specific survival, disease-free survival, overall survival, prognosis, progression-free survival, recurrence-free survival, red blood cell distribution width, urological malignancy
Copyright
Patients/Population/Participants
patients with urologic tumors
Intervention
Red blood cell distribution width (RDW)
Comparison
lower RDW
Outcome
poorer clinical outcomes, higher risk of death
Abstract
P
I
C
O
Red blood cell distribution width (RDW) is widely used in clinical practice and is routinely measured in blood tests. Recently RDW has been shown to be able to serve as an emerging marker for predicting clinical outcomes in patients with various types of cancer. The authors conducted a meta-analysis of 15 studies containing 9492 patients and showed that lower RDW in patients with urologic tumors may be associated with poorer clinical outcomes and a higher risk of death.